L26/P-122 Does routine microfluidics sperm sorting improve reproductive outcomes in POSEIDON group 3 women undergoing ICSI? A non-randomized observational cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.458 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Narula und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does routine use of microfluidics sperm sorting improve embryological and reproductive outcomes compared with density gradient preparation in POSEIDON group 3 women undergoing ICSI? Summary answer Routine microfluidics sperm-sorting didn’t improve live birth rates and was associated with lower implantation, despite modest improvements in blastocyst-development in POSEIDON group3 women What is known already POSEIDON group 3 women are young but have reduced ovarian reserve, leading to fewer oocytes retrieved, higher cycle cancellation rates, and limited embryo availability. Strategies such as oocyte pooling, repeated stimulation cycles, and preimplantation genetic testing for aneuploidy (PGT-A) have been explored, often increasing cost and treatment burden with variable benefit. Optimizing sperm selection represents a potentially modifiable factor. Microfluidics sperm sorting (MFSS), a centrifugation-free and physiological method, has demonstrated benefits in men with elevated sperm DNA fragmentation; however, its role as a cycle enhancer in POSEIDON group 3 women remains unclear. Study design, size, duration This non-randomized observational cohort study was conducted between 2019 and 2024. Outcomes were compared between a study group using microfluidics sperm sorting (MFSS) and a control group using conventional double density gradient (DDG) sperm preparation. A total of 268 ICSI cycles were included (MFSS: 151; DDG: 117). Inclusion criteria comprised POSEIDON group 3 women and normozoospermia male partners, while cycles involving PGT-A, donor gametes, or severe male factor infertility were excluded. Participants/materials, setting, methods All cycles underwent ICSI, extended blastocyst culture, and a freeze-all strategy. Frozen embryo transfer involved two good-quality blastocysts. MFSS used a centrifugation-free microfluidic device for progressive sperm selection, while DDG used conventional density gradient centrifugation. Outcomes included fertilization, blastocyst formation, cycle cancellation per oocyte retrieval cycle, implantation per embryo transfer cycles, clinical pregnancy, miscarriage, and live birth. Odds ratios(ORs) with 95% confidence intervals(CIs) were calculated; p < 0.05 was significant Main results and the role of chance Overall 268 cycles were analyzed (MFSS: 151; DDG: 117). Fertilization rates were comparable (87% vs 90%; OR 0.75, 95% CI 0.42–1.34; p = 0.33). MFSS demonstrated higher blastocyst formation (59% vs 51%; OR 1.38, 95% CI 0.96–1.99; p = 0.08) and day-5 blastocyst proportion (48% vs 42%; OR 1.27, 95% CI 0.88–1.83; p = 0.19), though differences were not statistically significant. Cycle cancellation due to no blastocyst formation was identical (17%; p = 0.98). After frozen embryo transfer, implantation was significantly lower with MFSS (44% vs 63%; OR 0.46, 95% CI 0.27–0.78; p = 0.004). Clinical pregnancy rates were 55% vs 66% (OR 0.63, 95% CI 0.36–1.11; p = 0.11). Miscarriage rates favored MFSS (5% vs 10%; OR 0.47, 95% CI 0.14–1.55; p = 0.21). Live birth was similar (50% vs 56%; OR 0.79, 95% CI 0.45–1.38; p = 0.40). These results indicate that modest embryological trends did not improve live birth outcomes and may reflect overriding oocyte quality constraints in POSEIDON group 3 women rather than additive benefit of MFSS. Limitations, reasons for caution The retrospective design, absence of sperm DNA fragmentation assessment, moderate sample size, and lack of adjustment for embryo-level clustering limit causal inference and statistical power. Wider implications of the findings In POSEIDON group 3 women with normozoospermia partners, routine MFSS does not improve live birth rates and may be associated with reduced implantation. These data support evidence-based restraint in routine use and suggest selective application only when clear indication exists. Trial registration number No
Zitieren
APA
Narula, R., Mantravadi, K., Gedela, D., Chauhan, V., & Venkatesh, S. (2026). L26/P-122 Does routine microfluidics sperm sorting improve reproductive outcomes in POSEIDON group 3 women undergoing ICSI? A non-randomized observational cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.458
Vancouver
Narula R, Mantravadi K, Gedela D, Chauhan V, Venkatesh S. L26/P-122 Does routine microfluidics sperm sorting improve reproductive outcomes in POSEIDON group 3 women undergoing ICSI? A non-randomized observational cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.458
BibTeX
@article{Narula2026,
author = {Narula, R. and Mantravadi, K.C. and Gedela, D.R. and Chauhan, V. and Venkatesh, S.R.},
title = {L26/P-122 Does routine microfluidics sperm sorting improve reproductive outcomes in POSEIDON group 3 women undergoing ICSI? A non-randomized observational cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.458}
}
EUVIMED